ceFAZolin sodium in Sterile Water for injection — Class II drug recall D-0141-2024
Completed recall by Wells Pharma of Houston LLC, reported 2023-12-13, distributed in PA. Lack of assurance of sterility.
| Recall number | D-0141-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Completed |
| Voluntary or mandated | Voluntary |
| Recalling firm | Wells Pharma of Houston LLC, Houston, TX, United States |
| Recall initiated | 2023-11-22 |
| Classified | 2023-12-06 |
| Reported by FDA | 2023-12-13 |
| Distributed | PA |
| Quantity | 825 syringes |
| Reason classes | sterility |
| NDC | 73702-0131-10 |
| Expiration dates | 2024-01-12 |
Product
ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10
Reason for recall
Lack of assurance of sterility.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0141-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.